NZCA Stock Overview
Provexis plc, together with its subsidiaries, develops, licenses, and sells functional foods, medical foods, and dietary supplements worldwide.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Provexis plc Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | UK£0.005 |
| 52 Week High | UK£0.0075 |
| 52 Week Low | UK£0.004 |
| Beta | 1.19 |
| 1 Month Change | 0% |
| 3 Month Change | -16.67% |
| 1 Year Change | -16.67% |
| 3 Year Change | -44.44% |
| 5 Year Change | 66.67% |
| Change since IPO | -89.13% |
Recent News & Updates
Recent updates
Shareholder Returns
| NZCA | DE Personal Products | DE Market | |
|---|---|---|---|
| 7D | -9.1% | 4.4% | 1.7% |
| 1Y | -16.7% | -2.0% | 2.3% |
Price Volatility
| NZCA volatility | |
|---|---|
| NZCA Average Weekly Movement | 16.9% |
| Personal Products Industry Average Movement | 4.7% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.1% |
| 10% least volatile stocks in DE Market | 2.4% |
Volatility Over Time: NZCA's weekly volatility (17%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1999 | 2 | Ian Ford | www.provexis.com |
Provexis plc, together with its subsidiaries, develops, licenses, and sells functional foods, medical foods, and dietary supplements worldwide. Its products include Fruitflow, a tomato extract that reduces the propensity for aberrant blood clotting typically associated with cardiovascular diseases, such as heart attack and stroke. The company’s syrup and powder versions of Fruitflow are used in various foods, beverages, and dietary supplement formats.
Provexis plc Fundamentals Summary
| NZCA fundamental statistics | |
|---|---|
| Market cap | €15.81m |
| Earnings (TTM) | -€578.35k |
| Revenue (TTM) | €696.56k |
22.7x
P/S Ratio-27.3x
P/E RatioIs NZCA overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| NZCA income statement (TTM) | |
|---|---|
| Revenue | UK£598.08k |
| Cost of Revenue | UK£318.64k |
| Gross Profit | UK£279.44k |
| Other Expenses | UK£776.03k |
| Earnings | -UK£496.59k |
Last Reported Earnings
Sep 30, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.00022 |
| Gross Margin | 46.72% |
| Net Profit Margin | -83.03% |
| Debt/Equity Ratio | 0% |
How did NZCA perform over the long term?
See historical performance and comparison